Verve Therapeutics is a genetic medicines company.
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. It has been purpose-built for the task ahead, with a team of experts in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 16, 2021 | IPO | $266.70M | — | — | — | Detail |
Jan 19, 2021 | Series B | $94M | 12 | Casdin Capital Wellington Management | — | Detail |
Jun 11, 2020 | Series A | $63M | 6 | GV | — | Detail |
May 7, 2019 | Series A | $58.50M | 4 | GV | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Casdin Capital | Yes | Series B |
Wellington Management | Yes | Series B |
Biomatics Capital Partners | — | Series B |
Cormorant Asset Management | — | Series B |
GV | — | Series B |
Janus Henderson Investors | — | Series B |
Logos Capital | — | Series B |
Novo Holdings | — | Series B |
RA Capital Management | — | Series B |
Redmile Group | — | Series B |